Lulia Al‐Hillawi
John Radcliffe Hospital(GB)University of Oxford(GB)
Publications by Year
Research Areas
Inflammatory Bowel Disease, Microscopic Colitis, Cancer Immunotherapy and Biomarkers, Systemic Lupus Erythematosus Research, Colorectal Cancer Screening and Detection
Most-Cited Works
- → Interferon-Gamma–Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor–Colitis(2021)190 cited
- → Pitfalls in histoacryl glue injection therapy for oesophageal, gastric and ectopic varices: A review(2016)43 cited
- → COVID-19 infection causing residual gastrointestinal symptoms – a single UK centre case series(2022)28 cited
- → Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis(2024)21 cited
- → Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study(2022)19 cited
- → Cancer Biology or Ineffective Surveillance? A Multicentre Retrospective Analysis of Colitis-Associated Post-Colonoscopy Colorectal Cancers(2023)9 cited
- → PTU-075 What is the benefit of telephone and virtual IBD clinics in a DGH?(2018)4 cited
- → OP06 HLA-DQA1*05:01 is associated with loss of response to infliximab, and HLA DQA1*05:05 with loss of response to adalimumab in the Oxford OASIS study(2025)2 cited
- → P371 Using digital monitoring during the COVID pandemic to streamline outpatient appointments(2021)1 cited
- → P0002 Identification of Infliximab and Adalimumab -derived peptides using MHC class II antibody mediated immunopeptidomics and mass spectrometry: implications for drug re-design(2025)1 cited